Search

A Post-Doctoral Research Fellowship has been funded under the European Union’s INTERREG VA Programme for a pioneering cross-border research project, designed to better understand and alleviate the impact of Chronic Obstructive Airways Disease (COPD). The BREATH project involves a strong cross-border partnership between the Smooth Muscle Research Centre (Dundalk Institute of Technology; DkIT), the School […]

Aaron joined Almac Discovery in 2016 and has responsibility for translational research activities including key external research collaborations.  Aaron has over 20 years of experience in preclinical oncology and left Mission Therapeutics, where he was Head of Pharmacology for the deubiquitylating enzyme (DUB) specialist, to join Discovery.  Aaron has also previously worked for PRECOS, a […]

Company Overview Almac Discovery is an innovative biotech company operating within and supported by the Almac Group of companies. It is led by an experienced team (ex-Pharma and Biotech), with a track record in delivering successful clinical programmes. Almac Discovery utilises its capabilities and expertise to discover and develop NCEs and Novel Protein Therapeutics through […]

Shape the future of drug discovery At Almac Discovery, we are driven by curiosity, innovation, and the ambition to deliver breakthrough medicines. As a highly research‑intensive biotech company, we focus on discovering and developing novel therapeutics that have the potential to redefine patient care. Our multidisciplinary team of scientists harnesses cutting‑edge technologies to create first‑in‑class, […]

Colin manages the medicinal chemistry, ADMET and CADD groups within Almac Discovery bringing to bear his experience in chemistry contract research from his 9 year tenure in Almac Sciences.

Company Overview Almac Discovery is a highly innovative biotech company led by a highly experienced team with a proven track record in delivering next generation therapeutics. We have partnered multiple therapeutic programs and our partners are advancing a number of these through clinical trials.  We leverage our deep expertise and integrated experience in protein engineering […]

Graham joined Almac from the acquisition of Albachem and subsequently joined Almac Discovery to bring expertise in peptide and protein chemistry. Graham has responsibility for the technical management of Discovery’s Protein Drug Conjugate key research focus within Almac Discovery and was important in the discovery of the peptide clinical candidate, ALM201.

Lisa joined Almac Discovery in 2016 and has responsibility for the project management of preclinical and clinical programmes. She has 10 years of mainly oncology experience gained across both drug development and stratified medicine.

We are a research-driven biotech company dedicated to the discovery of first-in-class therapies addressing unmet needs. Our platforms and portfolio deliver NCEs and protein therapeutics against novel targets of relevance in oncology and neurodegeneration. Partnered Programmes WEE1: Zedoresertib (DEBIO 0123), Ph1b, Oncology WEE1 is a key regulator of the G2/M and S phase checkpoints, activated […]

Science For almost two decades Almac Discovery has been innovating across therapeutic targets, disease indications and targeting modalities.  We have built deep internal expertise and collaborative networks that have enabled us to deliver scientific programs that fully align with our commitment to develop life-changing treatments for patients Building on our success in developing novel small […]

Stephen is a member of the Almac Group Executive Management and President and Managing Director of both Almac Discovery and Almac Sciences. He was instrumental in establishing Almac Discovery and has had overall responsibility for strategic, financial and operational leadership ever since.

Tim joined Almac Sciences in 2006 as Vice President of Research and Development before moving to Almac Discovery on its establishment in 2008: an initiative he had played a key role in planning and championing. He now has responsibility for all R&D activities and for coordinating the relationship with Queen’s University which, most recently, is […]

Ubiquitin specific protease 7 (USP7) is a member of the deubiquitinating enzyme class that contains 106 representatives in human cells. USP7 removes the post-translational tag ubiquitin from several protein targets 1.  USP7 best characterised role is the removal of ubiquitin from the oncogene MDM2 and thus regulating the tumour suppressor protein p53 2.  It has […]

Xavier joined Almac Discovery in 2018 and is leading the biology team for the company’s small molecule discovery. He has over 18 years of industry experience and a track record in early stage discovery and development for highly innovative oncology and CNS drug target classes.